These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

118 related articles for article (PubMed ID: 14663459)

  • 1. Population pharmacokinetics of enfuvirtide in pediatric patients with human immunodeficiency virus: searching for exposure-response relationships.
    Soy D; Aweeka FT; Church JA; Cunningham CK; Palumbo P; Kosel BW; Sheiner LB;
    Clin Pharmacol Ther; 2003 Dec; 74(6):569-80. PubMed ID: 14663459
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Population pharmacokinetics and exposure-response relationship of enfuvirtide in treatment-experienced human immunodeficiency virus type 1-infected patients.
    Mould DR; Zhang X; Nieforth K; Salgo M; Buss N; Patel IH
    Clin Pharmacol Ther; 2005 Jun; 77(6):515-28. PubMed ID: 15961983
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pharmacokinetics of plasma enfuvirtide after subcutaneous administration to patients with human immunodeficiency virus: Inverse Gaussian density absorption and 2-compartment disposition.
    Zhang X; Nieforth K; Lang JM; Rouzier-Panis R; Reynes J; Dorr A; Kolis S; Stiles MR; Kinchelow T; Patel IH
    Clin Pharmacol Ther; 2002 Jul; 72(1):10-9. PubMed ID: 12152000
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Population pharmacokinetics of enfuvirtide in HIV-1-infected pediatric patients over 48 weeks of treatment.
    Zhang X; Lin T; Bertasso A; Evans C; Dorr A; Kolis SJ; Salgo M; Patel I;
    J Clin Pharmacol; 2007 Apr; 47(4):510-7. PubMed ID: 17389560
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pharmacokinetics of enfuvirtide in pediatric human immunodeficiency virus 1-infected patients receiving combination therapy.
    Bellibas SE; Siddique Z; Dorr A; Bertasso A; Sista P; Kolis SJ; Cotler S; Delora P;
    Pediatr Infect Dis J; 2004 Dec; 23(12):1137-41. PubMed ID: 15626952
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Enfuvirtide, first fusion inhibitor in the treatment of human immunodeficiency virus infection: mechanism of action and pharmacokinetics].
    Raffi F
    Med Mal Infect; 2004 Sep; 34 Spec No 1():3-7. PubMed ID: 15742549
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Unaltered etanercept pharmacokinetics with concurrent methotrexate in patients with rheumatoid arthritis.
    Zhou H; Mayer PR; Wajdula J; Fatenejad S
    J Clin Pharmacol; 2004 Nov; 44(11):1235-43. PubMed ID: 15496641
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pharmacokinetic and pharmacodynamic determinants of early virological response to enfuvirtide-based regimens in HIV-positive patients.
    de Requena DG; Bonora S; Castagna A; Hasson H; Marucco DA; D'Avolio A; Sciandra M; Trentini L; Calcagno A; Lazzarin A; Di Perri G
    J Antimicrob Chemother; 2008 Aug; 62(2):384-7. PubMed ID: 18487231
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pharmacokinetics, pharmacodynamics and safety of once-daily versus twice-daily dosing with enfuvirtide in HIV-infected subjects.
    Thompson M; DeJesus E; Richmond G; Wheeler D; Flaherty J; Piliero P; True A; Chiu YY; Zhang Y; McFalls E; Miralles GD; Patel IH
    AIDS; 2006 Feb; 20(3):397-404. PubMed ID: 16439873
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Safety, tolerability, and plasma pharmacokinetics of high-strength formulations of enfuvirtide (T-20) in treatment-experienced HIV-1-infected patients.
    Wheeler DA; Lalezari JP; Kilby JM; Wheat J; Delehanty J; DeMasi R; Patel I; Salgo M
    J Clin Virol; 2004 Jun; 30(2):183-90. PubMed ID: 15125875
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Lack of interaction between enfuvirtide and ritonavir or ritonavir-boosted saquinavir in HIV-1-infected patients.
    Ruxrungtham K; Boyd M; Bellibas SE; Zhang X; Dorr A; Kolis S; Kinchelow T; Buss N; Patel IH
    J Clin Pharmacol; 2004 Jul; 44(7):793-803. PubMed ID: 15199084
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Mechanism-based model of the pharmacokinetics of enfuvirtide, an HIV fusion inhibitor.
    Mohanty U; Dixit NM
    J Theor Biol; 2008 Apr; 251(3):541-51. PubMed ID: 18258267
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pharmacokinetic bioequivalence of enfuvirtide using a needle-free device versus standard needle administration.
    True AL; Chiu YY; Demasi RA; Stout R; Patel I
    Pharmacotherapy; 2006 Dec; 26(12):1679-86. PubMed ID: 17125431
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pharmacokinetics of enfuvirtide in a patient with impaired renal function.
    Leen C; Wat C; Nieforth K
    Clin Infect Dis; 2004 Dec; 39(11):e119-21. PubMed ID: 15578350
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Lack of enzyme-inducing effect of rifampicin on the pharmacokinetics of enfuvirtide.
    Boyd MA; Zhang X; Dorr A; Ruxrungtham K; Kolis S; Nieforth K; Kinchelow T; Buss N; Patel IH
    J Clin Pharmacol; 2003 Dec; 43(12):1382-91. PubMed ID: 14615475
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Population pharmacokinetics and pharmacodynamics of nelfinavir and its active metabolite M8 in HIV-1-infected children.
    Crommentuyn KM; Scherpbier HJ; Kuijpers TW; Mathôt RA; Huitema AD; Beijnen JH
    Pediatr Infect Dis J; 2006 Jun; 25(6):538-43. PubMed ID: 16732153
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Safety and efficacy of enfuvirtide for 48 weeks as part of an optimized antiretroviral regimen in pediatric human immunodeficiency virus 1-infected patients.
    Wiznia A; Church J; Emmanuel P; Eppes S; Rowell L; Evans C; Bertasso A;
    Pediatr Infect Dis J; 2007 Sep; 26(9):799-805. PubMed ID: 17721374
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Population pharmacokinetic analysis of indinavir in HIV-infected patient treated with a stable antiretroviral therapy.
    Brendel K; Legrand M; Taburet AM; Baron G; Goujard C; Mentré F;
    Fundam Clin Pharmacol; 2005 Jun; 19(3):373-83. PubMed ID: 15910662
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Placental transfer of enfuvirtide in the ex vivo human placenta perfusion model.
    Ceccaldi PF; Ferreira C; Gavard L; Gil S; Peytavin G; Mandelbrot L
    Am J Obstet Gynecol; 2008 Apr; 198(4):433.e1-2. PubMed ID: 18241815
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Enfuvirtide: the first therapy to inhibit the entry of HIV-1 into host CD4 lymphocytes.
    Matthews T; Salgo M; Greenberg M; Chung J; DeMasi R; Bolognesi D
    Nat Rev Drug Discov; 2004 Mar; 3(3):215-25. PubMed ID: 15031735
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.